The National Health Institutions funded the trial, which recruited 25,871 male and female American women aged 50 or over, including 5,106 African Africans. Study participants were divided into four groups and were randomly assigned to take supplements or placebos, which were followed for an average of 5.3 years.
One group took 2,000 IU (international units) of vitamin D3 and 1 grams of omega-3 daily. The second group of vitamin D and a fake pillus was replaced by omega-3. He received a third group of omega-3 and vitamin D. placebo And the final group received two placebos.
Pharmavite LLC of Northridge, Calif., The vitamin D agents and corresponding placebos, and Pronova BioPharma from Norway and BASF Omacor, gave fish oil under the brand name Lovaza in the United States.
The results, published at The New England Journal of Medicine, are presented on Saturday at a American Heart Society conference in Chicago.
In many ways, the results are not surprising. The public has been hit by a consistent stream of information about the vitamin D health benefits in recent years, as studies have linked low levels of vitamin to conditions as diverse as diabetes, high blood pressure, cancer, heart disease and depression. Many primary care doctors are now experiencing patients' vitamin D levels regularly and declaring them defective, and supplementary sales have been neglected in recent years.
All along, however, critics have questioned whether vitamin D is just an indication of general health, and whether the threshold for a lack of installation was too high. The so-called vitamin is synthesized in the body when the skin is exposed to sunlight and is reduced by smoking, obesity, poor nutrition and other factors. Some foods, such as fatty fish, eggs and slaughtered milk, also contain vitamin D.
The Institute of Medicine in 2011 concluded that most Americans had enough vitamin D and that shortcomings had been overstated. The group also noted that reports of potential benefits with higher blood levels have been inconsistent.